Hey Jane Safety, Regulation & Compliance: An Independent Clinical Review

What Is Hey Jane and Is It Legitimate?

Hey Jane is a licensed telehealth platform. It operates in states where prescribing medication abortion and other reproductive health services via telehealth is legally permitted. Providers on the platform must hold state-specific licenses and, for mifepristone prescribing, must be certified under the FDA Risk Evaluation and Mitigation Strategy (REMS) program.

That last point matters more than any marketing claim. The REMS program for mifepristone requires prescribers to complete specific training, counsel patients on risks, and document gestational age. Any platform prescribing mifepristone outside REMS certification is operating illegally. Hey Jane has publicly stated its providers are REMS-certified, which is the baseline regulatory standard.

Being legitimate in a legal sense does not automatically mean a platform is the right fit for every woman. The sections below break down the clinical details you need to make that call yourself.

What Services Does Hey Jane Actually Offer?

Hey Jane's service menu covers:

• Medication abortion (mifepristone plus misoprostol, the standard two-drug regimen)
• Emergency contraception (oral levonorgestrel or ulipristal acetate)
• Birth control (oral contraceptives, patches, rings)
• STI testing and treatment (including chlamydia, gonorrhea, and BV)
• UTI treatment
• Genital herpes suppression

The breadth matters because a reproductive health platform that handles abortion without also offering contraception counseling and STI care creates gaps. Hey Jane's model does attempt to address the continuum, which is consistent with ACOG guidance that reproductive health care should be integrated, not siloed.

The Cash-Pay Model: What It Means for You

No insurance billing means no insurance-driven prior authorization delays. For time-sensitive services like emergency contraception or medication abortion, speed matters clinically. The tradeoff is that out-of-pocket costs can be prohibitive for lower-income women, and no insurance integration means no automatic coordination with your primary care record.

Medication Abortion Safety: The Clinical Evidence Base

Medication abortion via mifepristone plus misoprostol has one of the most extensively studied safety profiles in outpatient medicine. A 2021 systematic review published in Obstetrics & Gynecology found serious adverse events in fewer than 0.5% of cases, and efficacy rates of approximately 95 to 98% through 10 weeks of gestation.

The standard FDA-approved regimen is mifepristone 200 mg orally followed 24 to 48 hours later by misoprostol 800 mcg buccally. This is the regimen Hey Jane uses. Any platform deviating from the FDA-labeled regimen without documented evidence-based justification would be a red flag.

What the Evidence Says About Telehealth-Specific Delivery

The shift to telehealth medication abortion (also called TelAbortion or no-test medication abortion) has been studied directly. A 2021 prospective cohort study in Nature Medicine involving 1,390 patients found that a no-test telehealth model for medication abortion had a serious adverse event rate of 0.3%, comparable to in-person care. Complete abortion without additional intervention occurred in 94.7% of participants.

A 2022 study in JAMA Internal Medicine similarly found that telehealth medication abortion services resulted in outcomes equivalent to clinic-based care, with patients reporting high satisfaction and low rates of complications.

These numbers apply to the clinical model, not to any specific platform. Hey Jane operates within this model, so the underlying safety data is relevant, but individual outcomes depend on provider quality, patient selection, and follow-up systems.

Serious Risks Every Woman Should Know

Serious complications are rare but real. They include:

• Incomplete abortion, requiring aspiration in approximately 2 to 5% of cases
• Heavy bleeding requiring transfusion in roughly 0.03 to 0.5% of cases
• Infection, including very rare cases of sepsis from Clostridium sordellii (fewer than 10 reported cases per million procedures)
• Ectopic pregnancy not identified pre-treatment, which is a potentially life-threatening emergency

The last point is the most consequential for telehealth. Mifepristone does not treat an ectopic pregnancy. Any platform using a no-test model must have a screening process that identifies warning signs of ectopic pregnancy and has a clear protocol for routing those patients to in-person care immediately. ACOG Practice Bulletin No. 225 is explicit that ruling out ectopic pregnancy is a prerequisite for medication abortion.

Hey Jane's intake process asks about ectopic pregnancy risk factors, but as with all asynchronous telehealth platforms, the accuracy of screening depends on patient-reported information. If you have a history of ectopic pregnancy, a prior tubal surgery, or an IUD in place, in-person evaluation before medication abortion is the safer path.

Pregnancy and Lactation: Required Safety Information

This section is mandatory in any WomanRx drug review because the stakes of misunderstanding are highest here.

Mifepristone in Pregnancy

Mifepristone is a progesterone receptor antagonist. It is used in medication abortion specifically because it blocks the progesterone needed to maintain a pregnancy. It is contraindicated for use in a continuing (desired) pregnancy. If you take mifepristone and the pregnancy continues, the FDA label notes potential risks to the fetus, including fetal abnormalities, though data are limited because the drug is used to terminate pregnancy.

If you want to continue a pregnancy, do not take mifepristone. This seems obvious, but telehealth platforms must have intake systems that clearly confirm this intent.

Misoprostol in Pregnancy

Misoprostol, used alone (without mifepristone) or in combination, carries its own risks if a pregnancy continues after exposure. Data from Brazil, where misoprostol was used extrajudicially before legalization, showed associations with limb defects and Möbius sequence when pregnancies continued after failed misoprostol use. This risk is why the follow-up confirmation of abortion completion is clinically essential, not optional.

Lactation Considerations

For women who are postpartum and lactating, the timing of medication abortion (if sought postpartum) matters. Mifepristone transfers into breast milk in small amounts. A pharmacokinetic study published in Contraception found peak mifepristone levels in breast milk at 2 to 3 hours post-dose. Withholding breastfeeding for 24 to 48 hours after mifepristone and discarding expressed milk during that window is a reasonable precaution, though the absolute infant exposure is low. Misoprostol has a very short half-life and is considered compatible with breastfeeding by most sources, including LactMed.

Contraception After Medication Abortion

Ovulation can resume as early as 8 to 10 days after a completed medication abortion, meaning pregnancy is possible before your next expected period. ACOG recommends starting contraception immediately after medication abortion if the patient does not want to become pregnant again. Hey Jane does offer contraception prescriptions, which means a provider should be discussing this during the same encounter. If no contraception discussion occurs, that is a quality gap worth noting.

Regulatory and Compliance Posture: What We Can Verify

REMS Certification

The FDA's REMS program for mifepristone (the Mifepristone REMS Program, formally the Mifeprex REMS) is the central regulatory framework. After the FDA updated the REMS in 2023 to allow certified pharmacies to dispense mifepristone, certified telehealth providers can now prescribe and patients can receive medication by mail or at a participating pharmacy. Hey Jane uses mail delivery in states where that is legally permitted.

Prescriber REMS certification is verifiable through individual state medical board records, though patients cannot easily look up individual certifications in a single database. This is a real transparency gap across the telehealth medication abortion sector, not unique to Hey Jane.

State-by-State Legal Exposure

After Dobbs v. Jackson Women's Health Organization (2022), the legal status of medication abortion varies by state. Hey Jane operates only in states where it is legal, and it restricts intake for patients in states where abortion is banned or restricted. This is the legally compliant approach. However, state law changes rapidly. Before initiating care, confirm that your state permits telehealth medication abortion at the time of your appointment, not just at the time you read this article.

The Guttmacher Institute tracks state abortion laws in real time, though this site is not on the WomanRx allowlist. For clinical guidance on your specific situation, ACOG's state policy resources provide clinician-facing context.

Prescribing Standards: What Good Looks Like

A compliant, high-quality telehealth medication abortion encounter should include:

1. Confirmation of gestational age (self-reported LMP with instruction to seek ultrasound if dates are uncertain)
2. Active screening for ectopic pregnancy risk factors
3. Confirmation of patient's voluntary decision
4. Counseling on expected symptoms, warning signs requiring emergency care, and follow-up plan
5. Clear instructions for completing the regimen
6. A follow-up mechanism (serum hCG, urine test, or telehealth check-in) to confirm completion
7. Discussion of contraception going forward

Whether Hey Jane's asynchronous intake fully meets all seven of these elements in every encounter is not independently verifiable from public data. Platforms that use entirely asynchronous (questionnaire-only) models without any synchronous touchpoint carry more risk of missing clinical nuance than platforms that include a live provider interaction.

Hey Jane vs. Alternatives: How Does It Compare?

Several telehealth platforms operate in the medication abortion and reproductive health space. Direct comparisons require caution because state availability, service scope, and pricing shift frequently.

Other Platforms in the Space

• Plan C / Aid Access: Aid Access prescribes via international providers for patients in restricted states, which operates outside FDA REMS jurisdiction. It serves an important access function but carries distinct regulatory and quality-assurance considerations. Plan C serves as an information hub rather than a prescriber.
• Choix: A California-based telehealth platform with medication abortion and contraception, using a similar model to Hey Jane.
• Planned Parenthood Direct: Planned Parenthood's telehealth arm offers medication abortion in select states, backed by a large clinical infrastructure.
• Wisp: Focuses heavily on STI treatment and sexual health, with some overlap on contraception but not medication abortion.

Hey Jane's niche is the combination of medication abortion with broader sexual and reproductive health services in a single cash-pay platform. For women who want one provider relationship for abortion care and ongoing contraception or STI management, that integration has real clinical value.

Where Hey Jane Has Documented Gaps

Based on publicly available information:

• No OBGYN-level care for complex cases: Hey Jane is appropriate for uncomplicated medication abortion within gestational limits. Women with significant medical comorbidities (coagulopathy, adrenal insufficiency, corticosteroid use, inherited porphyria, or IUD in situ) are contraindications per the FDA label and need in-person evaluation.
• Asynchronous model limits real-time assessment: A questionnaire cannot replace a clinical exam when exam findings would change management.
• Incomplete follow-up data: No published outcomes data specific to Hey Jane's patient population is available. The platform does not appear to contribute to peer-reviewed literature, which is an evidence transparency gap.

Who This Is Right For, and Who It Is Not

Women Who May Benefit

• Women in states where Hey Jane operates legally who are seeking medication abortion within the gestational limit
• Women with uncomplicated reproductive health needs (STI treatment, contraception, UTI) who prefer telehealth convenience
• Women without insurance coverage or with insurance that does not cover reproductive health services
• Women in reproductive years with no contraindications to the medications prescribed

Women Who Should Seek In-Person Care Instead

• Women with suspected or confirmed ectopic pregnancy (lower abdominal pain plus positive pregnancy test warrants in-person evaluation before any abortion medication)
• Women beyond Hey Jane's gestational cutoff for medication abortion
• Women with contraindications to mifepristone: chronic corticosteroid therapy, inherited porphyria, coagulopathy, or IUD in place that cannot be removed
• Women with complex medical histories that require clinical examination to safely prescribe
• Women in perimenopause who are uncertain whether their irregular cycles reflect perimenopause or pregnancy (irregular cycles make gestational dating by LMP unreliable; an ultrasound is necessary to confirm dates before medication abortion in this group)
• Postpartum women in the first 6 to 8 weeks after delivery, where incomplete uterine involution and hormonal fluctuation warrant in-person assessment

A Note on Perimenopausal Women

Perimenopause brings irregular, often unpredictable cycles. If you are in your 40s with cycle changes and a positive pregnancy test, do not assume you know your gestational age from LMP alone. Underestimating gestational age is the most common reason telehealth medication abortion is inappropriate for a given patient. An ultrasound to confirm dates is medically necessary in this scenario, and any platform that proceeds without it in a woman with irregular cycles is taking a clinically unjustifiable shortcut.

Sexual and Reproductive Health Beyond Abortion

Hey Jane's broader reproductive health services deserve attention because abortion is often how the platform is discussed, while the day-to-day utility is in ongoing sexual health management.

STI Treatment

CDC STI Treatment Guidelines (2021) support telehealth treatment of uncomplicated STIs (chlamydia, gonorrhea, BV, genital herpes) when accompanied by adequate testing and follow-up. Hey Jane facilitates at-home STI testing with prescription treatment based on results. This model is consistent with current guidelines for uncomplicated cases.

Women with recurrent or complex STIs, PID (pelvic inflammatory disease), or suspected gonorrhea requiring dual-drug therapy should be seen in person. ACOG and CDC guidelines specify that PID requires clinical examination to diagnose and that severe cases require parenteral antibiotics in an inpatient or clinical setting.

Emergency Contraception

Levonorgestrel emergency contraception (Plan B and generics) is available over the counter, so telehealth prescribing adds minimal value here unless the patient needs ulipristal acetate (ella), which does require a prescription. Ulipristal is more effective than levonorgestrel, particularly for women with a BMI above 26 kg/m², and it remains effective up to 120 hours after unprotected sex. A 2011 meta-analysis in The Lancet found ulipristal was significantly more effective than levonorgestrel across the 120-hour window. For heavier women, a telehealth prescription for ulipristal from a platform like Hey Jane could be genuinely more effective than an OTC levonorgestrel purchase.

What Women's Reviews Actually Tell Us (and What They Don't)

Online reviews of Hey Jane tend to cluster around medication abortion experiences. Common themes in patient-reported accounts include:

• Appreciation for speed of access and discreet mail delivery
• Concerns about communication delays in asynchronous platforms
• Positive reports of clear instructions for the regimen
• Occasional complaints about follow-up being patient-initiated rather than provider-initiated

Reviews are not a substitute for clinical outcome data. No platform-specific published clinical outcomes exist for Hey Jane as of this writing. That is an honest evidence gap, and it is one that applies to most telehealth reproductive health platforms. The underlying clinical model (telehealth medication abortion using the FDA-approved mifepristone/misoprostol regimen) is well-studied. The platform's specific implementation of that model is not independently audited in the peer-reviewed literature.

The WomanRx Safety Evaluation Framework for Telehealth Reproductive Platforms:

When evaluating any telehealth reproductive health platform, apply these five questions before initiating care:

1. Are prescribers licensed in your state and REMS-certified (for mifepristone)?
2. Does the intake process actively screen for ectopic pregnancy risk factors?
3. Is there a clear emergency protocol if complications arise?
4. Does the platform include a follow-up mechanism to confirm abortion completion?
5. Is contraception counseling included in the same encounter?

If a platform cannot clearly answer all five in its publicly available materials, contact their clinical support line and ask directly before submitting payment.